对英夫利西单抗或环孢素难治的急性重症溃疡性结肠炎三线救援治疗的有效性与安全性(REASUC研究)
多中心回顾性队列研究纳入78例对静脉激素难治且英夫利西单抗或环孢素治疗失败的急性重症溃疡性结肠炎患者,评估同一住院期间三线救援治疗的无结肠切除生存率与安全性。随访中位21周,29例(37%)行结肠切除术,26例(33%)报告不良事件,2例(2.6%)死亡。三线救援治疗使超过半数患者避免结肠切除,作者认为可考虑作为一种治疗策略。
要点
- 78例激素难治且英夫利西单抗或环孢素失败的急性重症溃疡性结肠炎患者接受三线救援治疗。
- 随访中位21周,29例(37%)行结肠切除术,26例(33%)报告不良事件,2例(2.6%)死亡。
- 三线救援治疗使超过半数患者避免结肠切除,作者认为可考虑作为一种治疗策略。
核心结论
- 三线救援治疗使超过半数对静脉激素难治且英夫利西单抗或环孢素失败的急性重症溃疡性结肠炎患者避免结肠切除,作者认为可考虑作为一种治疗策略。
研究设计与样本
- 多中心回顾性队列研究,纳入78例对静脉激素难治且英夫利西单抗或环孢素治疗失败、在同一住院期间接受三线治疗的急性重症溃疡性结肠炎患者。
- 因疾病活动或不良事件停用二线治疗的患者符合纳入条件。
- 采用逻辑回归分析评估短期无结肠切除生存率,采用Kaplan-Meier曲线和Cox回归模型进行长期评估。
主要发现
- 78例患者中,32例以英夫利西单抗、46例以环孢素作为二线救援治疗。
- 三线治疗为英夫利西单抗45例(58%)、环孢素17例(22%)、托法替布13例(17%)、乌司奴单抗3例(3.8%)。
- 随访中位21周期间,29例(37%)行结肠切除术。
- 78例患者中,分别有32例和18例在12周和52周时处于临床缓解。
- 末次访视时,25例仍在接受三线救援治疗,12例因临床缓解而停药。
临床怎么用
- 作者认为,三线救援治疗可考虑作为对静脉激素难治且英夫利西单抗或环孢素失败的急性重症溃疡性结肠炎患者的一种治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The advent of new therapeutic agents and the improvement of supporting care might change the management of acute severe ulcerative colitis (ASUC) and avoid colectomy. AIMS: To evaluate the colectomy-free survival and safety of a third-line treatment in patients with ASUC refractory to intravenous steroids and who failed either infliximab or ciclosporin. METHODS: Multicentre retrospective cohort study of patients with ASUC refractory to intravenous steroids who had failed infliximab or ciclosporin and received a third-line treatment during the same hospitalisation. Patients who stopped second-line treatment due to disease activity or adverse events (AEs) were eligible. We assessed short-term colectomy-free survival by logistic regression analysis. Kaplan-Meier curves and Cox regression models were used for long-term assessment. RESULTS: Among 78 patients, 32 received infliximab and 46 ciclosporin as second-line rescue treatment. Third-line treatment was infliximab in 45 (58%), ciclosporin in 17 (22%), tofacitinib in 13 (17%) and ustekinumab in 3 (3.8%). Colectomy was performed in 29 patients (37%) during follow-up (median 21 weeks). Of the 78 patients, 32 and 18 were in clinical remission at, respectively, 12 and 52 weeks. At the last visit, 25 patients were still on third-line rescue treatment, while 12 had stopped it due to clinical remission. AEs were reported in 26 (33%) patients. Two patients died (2.6%), including one following colectomy. CONCLUSION: Third-line rescue treatment avoided colectomy in over half of the patients with ASUC and may be considered a therapeutic strategy.
引用
- García MJ, Riestra S, Amiot A, et al. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study). Aliment Pharmacol Ther. 2024. PMID: 38445785. doi:10.1111/apt.17938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。